Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / Ordinary Shares
-
Shares outstanding
-
293,061,432
-
Total 13F shares
-
113,059,720
-
Share change
-
+633,363
-
Total reported value
-
$1,099,514,079
-
Put/Call ratio
-
31%
-
Price per share
-
$9.75
-
Number of holders
-
123
-
Value change
-
-$3,867,076
-
Number of buys
-
63
-
Number of sells
-
53
Institutional Holders of AbCellera Biologics Inc. - Ordinary Shares (ABCL) as of Q1 2022
As of 31 Mar 2022,
AbCellera Biologics Inc. - Ordinary Shares (ABCL) was held by
123 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
113,059,720 shares.
The largest 10 holders included
Capital World Investors, Allianz Asset Management GmbH, BAILLIE GIFFORD & CO, BAKER BROS. ADVISORS LP, SB Management Ltd, DCVC Bio GP, LLC, ORBIMED ADVISORS LLC, HARVARD MANAGEMENT CO INC, GUARDIAN CAPITAL ADVISORS LP, and Founders Fund VII Management, LLC.
This page lists
126
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.